GLP-1R agonists can redefine chronic disease treatment beyond diabetes and obesity
GlobalData’s latest report showcases an analysis of the GLP-1R agonists pipeline in multiple indications, highlighting the areas…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Mounjaro
Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes
Phase 3 SURPASS programme demonstrated that Mounjaro, whether used alone or with other diabetes medications, reduced A1C by up to…
GLP-1R agonists clinical trial design needs to be improved to reassure drugs’ benefits: GlobalData
According to GlobalData, there are over 50 clinical trials for type 2 diabetes or obesity treatment involving GLP-1R agonists
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
Top 20 global biopharma companies report 1.6 per cent per cent market cap growth to $3.67 tn in…
Four companies – Lilly (59.2 per cent), Novo Nordisk (51.5 per cent), Vertex Pharmaceuticals (41.4 per cent) and Regeneron…
Eli Lilly’s Mounjaro to become leading GLP-1 therapy for type 2 diabetes in NHS in UK: GlobalData
The National Institute for Health and Care Excellence (NICE) provided guidance in August 2023 explaining that where triple therapy…
Eli Lilly to invest $450 million more to expand capacity as obesity drug decision looms
The company has been struggling to meet strong demand for its incretin products, which include its diabetes drug Trulicity and…